All In Biotech

Drug Trial Radar · NCT07013487

A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 12,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

12,000

Planned (sponsor's estimate)

Start

Jun 11, 2025

Primary completion

Sep 6, 2031

Study completion Sep 6, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.

Conditions

  • Healthy

Interventions

  • V181Biological

    Participants will receive a single 0.5 mL SC dose of V181 on Day 1.

  • PlaceboBiological

    Participants will receive a single 0.5 mL SC dose of placebo on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing a Medically Attended Adverse Event (MAAE)Time frame: Up to approximately 6 months postvaccination
  2. Percentage of Participants Experiencing a Serious Adverse Event (SAE)Time frame: Up to approximately 5 years postvaccination
  3. Reactogenicity and Immunogenicity Subset: Percentage of Participants Experiencing Solicited Injection-site AEsTime frame: Up to approximately 5 days postvaccination
  4. Reactogenicity and Immunogenicity Subset: Percentage of Participants Experiencing Solicited Systemic AEsTime frame: Up to approximately 28 days postvaccination
  5. Percentage of Participants Experiencing Symptomatic (Requiring Fever on at Least 2 of 3 Consecutive Days) VCD of Any Severity, Due to Any of the 4 Dengue Serotypes, Regardless of Dengue Serostatus at BaselineTime frame: Up to approximately 3 years postvaccination

Locations

41 sites in 7 countries. Site status is shown where the registry gives one.

  • Jatinegara Primary Health Center ( Site 0102)

    East Jakarta, Jakarta Special Capital Region, Indonesia

  • Cipayung Primary Health Center ( Site 0105)

    East Jakarta, Jakarta Special Capital Region, Indonesia

  • Dr Cipto Mangunkusumo Hospital-Pediatrics ( Site 0101)

    Jakarta, Jakarta Special Capital Region, Indonesia

  • Kelapa Gading Primary Health Center ( Site 0104)

    North Jakarta, Jakarta Special Capital Region, Indonesia

  • Pasar Minggu Primary Health Center ( Site 0103)

    South Jakarta, Jakarta Special Capital Region, Indonesia

  • Hospital Tunku Azizah-Paediatric ( Site 0022)

    Kuala Lumpur, Malaysia

  • Hospital Pakar Kanak - Kanak UKM (HPKK) ( Site 0024)

    Cheras, Kuala Lumpur, Malaysia

  • University Malaya Medical Centre-Department of Paediatrics ( Site 0025)

    Lembah Pantai, Kuala Lumpur, Malaysia

  • Hospital Sibu ( Site 0021)

    Sibu, Sarawak, Malaysia

  • Hospital Ampang ( Site 0028)

    Ampang, Selangor, Malaysia

  • Hospital Al-Sultan Abdullah - Universiti Teknologi MARA ( Site 0029)

    Bandar Puncak Alam, Selangor, Malaysia

  • Sunway Medical Centre ( Site 0027)

    Petaling Jaya, Selangor, Malaysia

  • Health Index Multispecialty And Lying-In Clinic ( Site 0042)

    Bacoor, Cavite, Philippines

  • Chong Hua Hospital ( Site 0051)

    Cebu City, Cebu, Philippines

  • Norzel Medical and Diagnostic Clinic Foundation Corp ( Site 0044)

    Cebu City, Central Visayas (Region VII), Philippines

  • West Visayas State University Medical Center ( Site 0045)

    Iloilo City, Iloilo, Philippines

  • Philippine General Hospital ( Site 0041)

    Manila, National Capital Region, Philippines

  • University of the Philippines Manila ( Site 0047)

    Metro Manila, National Capital Region, Philippines

  • Clinical Research Investigator Group ( Site 0110)

    Bayamón, Puerto Rico

  • San Juan Bautista School of Medicine - Clinical Research Unit ( Site 0114)

    Caguas, Puerto Rico

  • Ponce Medical School Foundation Inc./CAIMED Center ( Site 0112)

    Ponce, Puerto Rico

  • Latin Clinical Trial Center ( Site 0113)

    San Juan, Puerto Rico

  • Wellness clinical Research Vega Baja ( Site 0116)

    Vega Baja, Puerto Rico

  • National University Hospital-Paediatrics ( Site 0001)

    Singapore, Central Singapore, Singapore

  • KK Women's and Children's Hospital ( Site 0002)

    Singapore, Central Singapore, Singapore

  • Tan Tock Seng Hospital ( Site 0003)

    Singapore, Central Singapore, Singapore

  • Chulalongkorn University-Pediatrics ( Site 0063)

    Bangkok, Bangkok, Thailand

  • Faculty of Tropical Medicine, Mahidol University ( Site 0062)

    Bangkok, Bangkok, Thailand

  • Queen Sirikit National Institute of Child Health-Pediatric Infectious Disease ( Site 0071)

    Bangkok, Bangkok, Thailand

  • Faculty of Medicine Siriraj Hospital-Pediatric Infectious Diseases ( Site 0065)

    Bangkok, Bangkok, Thailand

  • Faculty of Tropical Medicine, Mahidol University - Vaccine Trial Centre ( Site 0067)

    Ratchathewi, Bangkok, Thailand

  • Kamphaeng Phet-AFRIMS Virology Research Unit KAVRU ( Site 0070)

    Muang, Changwat Kamphaeng Phet, Thailand

  • Faculty of Medicine - Khon Kaen University-Pediatrics ( Site 0064)

    Amphoe Mueang, Changwat Khon Kaen, Thailand

  • Thammasat University Hospital-Department of Pediatrics ( Site 0068)

    Khong Luang, Changwat Pathum Thani, Thailand

  • Songklanagarind hospital-Department of Pediatrics ( Site 0061)

    Hat Yai, Changwat Songkhla, Thailand

  • Maharaj Nakorn Chiang Mai Hospital ( Site 0066)

    Muang, Chiang Mai, Thailand

  • Quang Nam Hospital for Women and Children ( Site 0094)

    Da Nang, Vietnam

  • Dong Thap General Hospital ( Site 0092)

    Dong Thập, Vietnam

  • Pasteur Institute in Ho Chi Minh city ( Site 0089)

    Ho Chi Minh City, Vietnam

  • Kien Giang Women's and Children hospital ( Site 0091)

    Rach Gia, An Giang, Vietnam

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.